Mink Therapeutics Inc INKT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/22/24 EDT
1.00quote price arrow up+0.01 (+1.01%)
Volume
80,278
52 week range
0.75 - 3.34
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.00
  • 52 Week High3.34
  • 52 Week High Date06/22/23
  • 52 Week Low0.75
  • 52 Week Low Date01/16/24

Key Stats

  • Market Cap39.368M
  • Shares Out39.37M
  • 10 Day Average Volume0.62M
  • Dividend-
  • Dividend Yield-
  • Beta0.03
  • YTD % Change-6.54

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.00
  • 52 Week High3.34
  • 52 Week High Date06/22/23
  • 52 Week Low0.75
  • 52 Week Low Date01/16/24
  • Market Cap39.368M
  • Shares Out39.37M
  • 10 Day Average Volume0.62M
  • Dividend-
  • Dividend Yield-
  • Beta0.03
  • YTD % Change-6.54

RATIOS/PROFITABILITY

  • EPS (TTM)-0.60
  • P/E (TTM)-1.68
  • Fwd P/E (NTM)-2.00
  • EBITDA (TTM)-20.684M
  • ROE (TTM)-1,238.98%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-20.75%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Mink Therapeutics Inc

 

Profile

MORE
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy...
Garo Armen Ph.D.
Chairman of the Board
Jennifer Buell Ph.D.
President, Chief Executive Officer, Director
Address
149 Fifth Avenue, Suite 500
New York, NY
10010
United States

Top Peers

SYMBOLLASTCHG%CHG
IINN
Inspira Technologies Oxy BHN Ltd
2.19+0.01+0.46%
UNCY
Unicycive Therapeutics Inc
1.00-0.04-3.37%
QNCX
Quince Therapeutics Inc
0.89+0.03+3.4884%
EYEN
Eyenovia Inc
0.7459+0.0087+1.1801%
ACHL
Achilles Therapeutics PLC
0.90-0.0438-4.6408%